Fig. 3From: Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in ItalyResults of the probabilistic sensitivity analysis. ESC = escalation strategy; SWI = switching strategy. Willingness-to-pay threshold at €50,000 per QALY gainedBack to article page